All In Biotech

Drug Trial Radar · NCT06663189

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over: A Multicentric, Randomized, Controlled, Open-label Clinical Trial (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Last checked: Nov 20, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 2025

Primary completion

Jan 2027

Study completion Jun 2029

Sponsor

Lead sponsor
University Hospital, Strasbourg, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. It is the most common cause of neurological disability in young adults, involving a long-term therapeutic follow-up. 85% of the patients are diagnosed with Relapsing-Remitting form of MS (RRMS). This form is characterized by clearly defined acute or subacute neurological symptoms (relapses) followed by periods of partial to complete recovery. Disease-modifying therapies (DMT) used to treat RRMS are immunomodulatory or suppressor molecules which have proven efficacy in limiting disease activity (decreasing relapse rate and delaying time to disease progression). However, the long-term safety of DMT is uncertain, as there is an increased risk of developing adverse events or infections (sometimes severe) such as observed in the last pandemic of COVID-19 (higher risk of infection), highlighting the need to reassess the benefit/risk ratio of maintaining immunomodulatory or suppressive therapy in the MS population. In elderly patients with comorbidity, this risk is further increased. To date, few studies on the discontinuation of treatment in elderly RRMS patients have been conducted. However, those available demonstrate that there was no difference in relapse rates between patients who continued or discontinued treatment. These results are consistent with immunosenescence studies in RRMS that suggested a negative correlation between relapse rate/inflammatory processes and age. On the contrary, there is evidence indicating a positive correlation between age and the number of infections. In addition, in the current context in France, it is important to take into account the medico-social cost associated with long-term treatments. In France, the average estimated annual cost per patient is 12,000€, more than half of which is attributed to medications.Furthermore, with age progression, an inversion of the benefit/cost assessment has been observed in treated patients. Considering these medical and medico-social factors, it is reasonable to question the value of continuing treatment in stable patients with RRMS over 55 years. This is a randomized, controlled, multicentric, open-label, parallel groups, 1:1 ratio non-inferiority clinical trial, comparing (1) a group that will stop treatment, to (2) a group that will continue treatment, over the course of 2 years, to determine the survival rate without MS activity defined clinically or by imaging. The patients in both arms will be followed over 2 years after randomization. 5 visits will be performed for all patients: inclusion/randomization visit (M0) and 4 follow-up visits every 6 months (M6, M12, M18, and M24). An additional phone call at M3 is planned.

Conditions

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

  • treatment withdrawalDrug

    Patients will STOP their DMT

  • Usual DMT continuationDrug

    Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate

  • MRIOther

    Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit

  • Quality of Life questionnairesBehavioral

    EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire

  • Disability evaluation testsOther

    EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first clinical and/or radiological disease activity during a period of 2 years.Time frame: From enrollment to the end of study visit at 24 months

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Bordeaux-Hôpital Pellegrin

    Bordeaux, France

  • CHU de Caen-Hôpital Côte de Nacre

    Caen, France

  • CHU de Clermont-Ferrand-Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Henri Mondor

    Créteil, France

  • CHU de Dijon-Hôpital du Bocage

    Dijon, France

  • CH de Gonesse

    Gonesse, France

  • CHU de Grenoble Alpes

    La Tronche, France

  • Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital Saint Vincent de Paul

    Lille, France

  • CHU de Lille-Hôpital Roger Salengro

    Lille, France

  • CHU de Limoges-Hôpital Dupuytren

    Limoges, France

  • Assistance Publique des Hôpitaux de Marseille (APHM)-Hôpital La Timone Adultes

    Marseille, France

  • CHU de Montpellier-Hôpital G. De Chauliac

    Montpellier, France

  • CHU de Nancy -Hôpital Central

    Nancy, France

  • CHU de Nice-Hôpital Pasteur

    Nice, France

  • CHU de Nîmes

    Nîmes, France

  • Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Pitié-Salpêtrière

    Paris, France

  • Fondation Ophtalmologique Rothschild

    Paris, France

  • CHU de Rennes-C.H.R. Pontchaillou

    Rennes, France

  • CHU de Rouen-Hôpital Charles Nicolle

    Rouen, France

  • CHU Nantes -CIC de Neurologie

    Saint-Herblain, France

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • CHU de Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.